Relation of long-term exposure to subcutaneous interferon-β-1a with clinical outcomes in patients with relapsing-remitting multiple sclerosis: exploratory analyses from the PRISMS-15 study

被引：0

作者：

Kappos, L.

Cornelisse, P.

Lehr, L.

Kuhle, J.

Uitdehaag, B.

机构：

[1] Univ Basel Hosp, CH-4031 Basel, Switzerland

[2] Merck Serono SA, Geneva, Switzerland

[3] Vrije Univ Amsterdam, Med Ctr, Amsterdam, Netherlands

来源：

MULTIPLE SCLEROSIS JOURNAL | 2012年 / 18卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

引用

页码：39 / 39

页数：1

共 50 条

[1] Factors influencing long-term outcomes in relapsing-remitting multiple sclerosis: PRISMS-15
Kappos, Ludwig
Kuhle, Jens
Multanen, Juha
Kremenchutzky, Marcelo
di Cantogno, Elisabetta Verdun
Cornelisse, Peter
Lehr, Lorenz
Casset-Semanaz, Florence
Issard, Delphine
Uitdehaag, Bernard M. J.
[J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2015, 86 (11): : 1202 - 1207
[2] Baseline predictors of mortality in patients with relapsing-remitting multiple sclerosis: exploratory analyses from the PRISMS-15 study
Cornelisse, P.
Lehr, L.
Baldinetti, F.
[J]. MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 222 - 222
[3] Continuous versus non-continuous subcutaneous interferon β-1a treatment in relapsing-remitting multiple sclerosis: long-term data from the PRISMS study
Uitdehaag, B.
Kappos, L.
Verdun, E.
Gardner, J.
[J]. JOURNAL OF NEUROLOGY, 2009, 256 : S122 - S123
[4] Spotlight on Subcutaneous Recombinant Interferon-β-1a (Rebif®) in Relapsing-Remitting Multiple Sclerosis
David Murdoch
Katherine A. Lyseng-Williamson
[J]. BioDrugs, 2005, 19 : 323 - 325
[5] Spotlight on subcutaneous recombinant interferon-β-1a (Rebif®) in relapsing-remitting multiple sclerosis
Murdoch, D
Lyseng-Williamson, KA
[J]. BIODRUGS, 2005, 19 (05) : 323 - 325
[6] Long-term cost effectiveness of interferon-β-1a in the treatment of relapsing-remitting multiple sclerosis -: An econometric model
Lepen, C
Coyle, P
Vollmer, T
Blumhardt, L
Lilliu, H
Beresniak, A
[J]. CLINICAL DRUG INVESTIGATION, 2003, 23 (09) : 571 - 581
[7] Prognostic factors for long-term outcomes in relapsing-remitting multiple sclerosis: exploratory analysis of 15-year data from the PRISMS study
Kappos, L.
Uitdehaag, B.
Kuhle, J.
Issard, D.
Casset-Semanaz, F.
[J]. JOURNAL OF NEUROLOGY, 2013, 260 : S14 - S15
[8] Long-term treatment with subcutaneous interferon β-1a in relapsing-remitting multiple sclerosis: exploratory analysis of cumulative time and dose impact on clinical and magnetic resonance imaging outcomes
Uitdehaag, B.
Kappos, L.
Verdun, E.
Gardner, J.
[J]. JOURNAL OF NEUROLOGY, 2009, 256 : S123 - S123
[9] Cumulative dose-effect of up to 15 years of subcutaneous interferon beta-1a on clinical outcomes in relapsing-remitting multiple sclerosis: exploratory analysis of patients from the PRISMS study
Kappos, L.
di Cantogno, E. Verdun
Cornelisse, P.
Kuhle, J.
Uitdehaag, B.
[J]. JOURNAL OF NEUROLOGY, 2012, 259 : S110 - S110
[10] Long-term safety and tolerability of interferon β-1a in relapsing-remitting multiple sclerosis (RRMS):: Four-year data from the PRISMS study
Rieckmann, P
Gold, R
[J]. NEUROLOGY, 2001, 56 (08) : A354 - A354

← 1 2 3 4 5 →